JP6839184B2 - インドリン−２−オン誘導体 - Google Patents
インドリン−２−オン誘導体 Download PDFInfo
- Publication number
- JP6839184B2 JP6839184B2 JP2018522572A JP2018522572A JP6839184B2 JP 6839184 B2 JP6839184 B2 JP 6839184B2 JP 2018522572 A JP2018522572 A JP 2018522572A JP 2018522572 A JP2018522572 A JP 2018522572A JP 6839184 B2 JP6839184 B2 JP 6839184B2
- Authority
- JP
- Japan
- Prior art keywords
- dimethyl
- methylpyrimidine
- indolin
- pyrazine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AFOYFIWRUXOWDV-UHFFFAOYSA-N CC(C)(c(c(N1c(cc2)nc3c2c(C)n[n]3C)c2)ccc2-c2cnc(C)nc2)C1=O Chemical compound CC(C)(c(c(N1c(cc2)nc3c2c(C)n[n]3C)c2)ccc2-c2cnc(C)nc2)C1=O AFOYFIWRUXOWDV-UHFFFAOYSA-N 0.000 description 2
- BZKFGJNNBXJWTJ-UHFFFAOYSA-N CC(C)(c(c(N1C2COC2)c2)ccc2N2c3cc(-c4cnc(C)nc4)ccc3C(C)(C)C2=O)C1=O Chemical compound CC(C)(c(c(N1C2COC2)c2)ccc2N2c3cc(-c4cnc(C)nc4)ccc3C(C)(C)C2=O)C1=O BZKFGJNNBXJWTJ-UHFFFAOYSA-N 0.000 description 1
- PKNPDKOEWZQGCD-UHFFFAOYSA-N CC(C)(c(c(N1c(cc2C3(C)C)nnc2N(C)C3=O)c2)ccc2-c2cnc(C)nc2)C1=O Chemical compound CC(C)(c(c(N1c(cc2C3(C)C)nnc2N(C)C3=O)c2)ccc2-c2cnc(C)nc2)C1=O PKNPDKOEWZQGCD-UHFFFAOYSA-N 0.000 description 1
- NHRJZHBUNAXEAH-UHFFFAOYSA-N CC(C)(c(c(N1c(nc2N3)cnc2N(C)C3=O)c2)ccc2-c2cnc(C)nc2)C1=O Chemical compound CC(C)(c(c(N1c(nc2N3)cnc2N(C)C3=O)c2)ccc2-c2cnc(C)nc2)C1=O NHRJZHBUNAXEAH-UHFFFAOYSA-N 0.000 description 1
- LPQZXFAKLZIAFI-UHFFFAOYSA-N CC(C)(c(c(N1c2cc(C(C)(C)C(N3C)=O)c3nc2)c2)ccc2-c2cnc(C)nc2)C1=O Chemical compound CC(C)(c(c(N1c2cc(C(C)(C)C(N3C)=O)c3nc2)c2)ccc2-c2cnc(C)nc2)C1=O LPQZXFAKLZIAFI-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(c(c(N1c2cnc(*)c(N(*)*)n2)c2)ccc2-c2cnc(C)nc2)C1=O Chemical compound CC(C)(c(c(N1c2cnc(*)c(N(*)*)n2)c2)ccc2-c2cnc(C)nc2)C1=O 0.000 description 1
- CHYLOBFKSRZDPO-UHFFFAOYSA-N CC(C)(c(c(N1c2cncc(N(CC3)CCC3O)n2)c2)ccc2-c2cnc(C)nc2)C1=O Chemical compound CC(C)(c(c(N1c2cncc(N(CC3)CCC3O)n2)c2)ccc2-c2cnc(C)nc2)C1=O CHYLOBFKSRZDPO-UHFFFAOYSA-N 0.000 description 1
- VQUUNAVAHHXYHB-UHFFFAOYSA-N CC(C)(c1cc(Cl)nnc1N1C)C1=O Chemical compound CC(C)(c1cc(Cl)nnc1N1C)C1=O VQUUNAVAHHXYHB-UHFFFAOYSA-N 0.000 description 1
- DCRFVYQCFAQNFD-UHFFFAOYSA-N Cc(c(NCCOC)n1)ncc1Cl Chemical compound Cc(c(NCCOC)n1)ncc1Cl DCRFVYQCFAQNFD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15193355 | 2015-11-06 | ||
| EP15193355.3 | 2015-11-06 | ||
| PCT/EP2016/076315 WO2017076842A1 (en) | 2015-11-06 | 2016-11-02 | Indolin-2-one derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538253A JP2018538253A (ja) | 2018-12-27 |
| JP2018538253A5 JP2018538253A5 (enExample) | 2019-11-28 |
| JP6839184B2 true JP6839184B2 (ja) | 2021-03-03 |
Family
ID=54476823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522572A Active JP6839184B2 (ja) | 2015-11-06 | 2016-11-02 | インドリン−２−オン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10519140B2 (enExample) |
| EP (1) | EP3371174B1 (enExample) |
| JP (1) | JP6839184B2 (enExample) |
| CN (1) | CN108137561B (enExample) |
| AR (1) | AR106589A1 (enExample) |
| TW (1) | TWI614244B (enExample) |
| WO (1) | WO2017076842A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050083T2 (hu) | 2015-11-06 | 2020-11-30 | Hoffmann La Roche | Indolin-2-on származékok |
| JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 |
| EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
| JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス， インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| WO2021231933A1 (en) * | 2020-05-15 | 2021-11-18 | Neucyte Pharmaceuticals | Anti-epileptic pharmaceutical compositions and use thereof |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| CN122122140A (zh) * | 2024-09-27 | 2026-05-29 | 成都麻沸散医药科技有限公司 | 一种化合物及其制备方法和用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| TW251284B (enExample) | 1992-11-02 | 1995-07-11 | Pfizer | |
| DE4427648A1 (de) | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
| FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
| WO2000040581A1 (en) | 1999-01-07 | 2000-07-13 | American Home Products Corporation | 3,4-dihydro-2h-benzo[1,4]oxazine derivatives |
| EP1303269B1 (en) | 2000-06-29 | 2005-12-07 | NeuroSearch A/S | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| WO2004060902A2 (en) | 2002-12-31 | 2004-07-22 | John K Buolamwini | Novel nucleoside transport inhibitors |
| SK51052006A3 (sk) | 2004-05-11 | 2007-05-03 | Egis Gy�gyszergy�r Nyrt. | Pyridínové deriváty alkyloxindolov ako aktívne látky voči 5-HT7 receptoru |
| US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| MX2008016083A (es) | 2006-06-26 | 2009-03-20 | Helicon Therapeutics Inc | Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3. |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| EP2114921B1 (en) | 2006-12-30 | 2012-12-26 | Abbott GmbH & Co. KG | Substituted oxindole derivative and its use as a vasopressin receptor ligand |
| UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| JO3126B1 (ar) * | 2007-11-14 | 2017-09-20 | Janssen Pharmaceutica Nv | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| ES2590531T3 (es) | 2012-09-13 | 2016-11-22 | F. Hoffmann-La Roche Ag | 2-oxo-2,3-dihidro-indoles para el tratamiento de trastornos del SNC |
| KR101811549B1 (ko) * | 2013-06-19 | 2017-12-26 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체 |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| PE20161476A1 (es) * | 2014-06-26 | 2017-01-07 | Hoffmann La Roche | Derivados de indolin-2-ona o pirrolo-piridin-2-ona |
| EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
| JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体 |
| JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 |
| HUE050083T2 (hu) | 2015-11-06 | 2020-11-30 | Hoffmann La Roche | Indolin-2-on származékok |
-
2016
- 2016-11-02 EP EP16790588.4A patent/EP3371174B1/en active Active
- 2016-11-02 JP JP2018522572A patent/JP6839184B2/ja active Active
- 2016-11-02 CN CN201680056575.2A patent/CN108137561B/zh active Active
- 2016-11-02 WO PCT/EP2016/076315 patent/WO2017076842A1/en not_active Ceased
- 2016-11-04 AR ARP160103364A patent/AR106589A1/es unknown
- 2016-11-04 TW TW105135829A patent/TWI614244B/zh not_active IP Right Cessation
-
2018
- 2018-05-04 US US15/971,368 patent/US10519140B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10519140B2 (en) | 2019-12-31 |
| TWI614244B (zh) | 2018-02-11 |
| CN108137561A (zh) | 2018-06-08 |
| WO2017076842A1 (en) | 2017-05-11 |
| EP3371174B1 (en) | 2021-03-17 |
| JP2018538253A (ja) | 2018-12-27 |
| CN108137561B (zh) | 2021-03-26 |
| EP3371174A1 (en) | 2018-09-12 |
| AR106589A1 (es) | 2018-01-31 |
| US20180251450A1 (en) | 2018-09-06 |
| TW201726653A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6857653B2 (ja) | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 | |
| TWI614244B (zh) | 吲哚啉-２-酮衍生物 | |
| JP6857662B2 (ja) | インドリン−２−オン誘導体 | |
| JP6857651B2 (ja) | Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体 | |
| HK1254785B (en) | Indolin-2-one derivatives | |
| HK1254785A1 (en) | Indolin-2-one derivatives | |
| BR112018008056B1 (pt) | Derivados de indolin-2-ona, seu uso e composição farmacêutica que os compreende | |
| HK1257169B (en) | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191016 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210104 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210209 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6839184 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |